This article is more than 5 years old. Information may no longer be current.
Debridement offers no advantage in treating microsporidial keratoconjunctivitis
Click Here to Manage Email Alerts
Corneal debridement showed no distinct advantage in resolving corneal lesions and improving vision in eyes treated for microsporidial keratoconjunctivitis, a study found.
The prospective, double-masked, randomized study included 120 patients with clinical features indicative of microsporidial superficial keratoconjunctivitis.
Fifty-eight patients underwent debridement, and 62 patients underwent conjunctival swabbing. All patients received ocular lubricants.
The primary outcome measure was time to full resolution of clinical signs and symptoms. Secondary outcome measures were final Snellen visual acuity and residual corneal side effects and/or scarring. Patients were examined at 1, 3 and 7 days and every week until clinical signs and symptoms resolved.
Mean time to resolution of corneal lesions was 5.7 days in the debridement group and 5.9 days in the swabbing group. Final visual acuity was 0.14 in the debridement group and 0.18 in the swabbing group. Scarring was identified in 34.3% of patients in the debridement group and 28.6% of patients in the swabbing group. These differences were not statistically significant.
Disclosure: The authors have no relevant financial disclosures.
Click Here to Manage Email Alerts